A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants with Gastrointestinal Malignancies
Study to Evaluate AB680 Combination Therapy in Participants with Gastrointestinal Malignancies
Sponsor: Arcus Biosciences, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS7260
U.S. Govt. ID: NCT04104672
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study is being done to see if potential new drugs, AB680 and AB122, can be safely given in combination with chemotherapy to study patients with pancreatic cancer. The standard chemotherapy treatments that will be given in combination with AB680 and AB122 are nab-paclitaxel and gemcitabine. AB680 and AB122 are not approved by the United States Food and Drug Administration (U.S. FDA).
Investigator
Gulam Manji, MD, PhD
Do You Qualify?
Are you at least 18 years old? Yes No
Do you have confirmed metastatic pancreatic adenocarcinoma? Yes No
Have you had any prior treatment, including chemotherapy, biological therapy, or targeted therapy for metastatic disease? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE